AZD9567 Monohydrat + Placebo oral suspension/ Placebo capsule + Prednisolone
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Safety
Conditions
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Healthy Subjects, Rheumatoid Arthritis
Trial Timeline
Nov 18, 2015 → Sep 26, 2016
NCT ID
NCT02512575About AZD9567 Monohydrat + Placebo oral suspension/ Placebo capsule + Prednisolone
AZD9567 Monohydrat + Placebo oral suspension/ Placebo capsule + Prednisolone is a phase 1 stage product being developed by AstraZeneca for Safety. The current trial status is completed. This product is registered under clinical trial identifier NCT02512575. Target conditions include Safety, Tolerability, Pharmacokinetics.
What happened to similar drugs?
3 of 4 similar drugs in Safety were approved
Approved (3) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02512575 | Phase 1 | Completed |
Competing Products
20 competing products in Safety